MBIO — Mustang Bio Inc
NASDAQ · Healthcare · Biotechnology
$0.55
+$0.01 (+1.97%)
Mustang Bio Inc (MBIO) is a biotechnology company listed on NASDAQ. It is led by Manuel Litchman M.D., based in 95 Sawyer Road, Waltham, MA, United States, 02453, with about 6 employees. Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Net income was -$468.0K. MBIO currently screens at market cap $11.6M.
Use this MBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Mustang Bio Inc even when a live quote feed is slow.
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
MBIO Key Statistics
Market Cap
$11.60M
Volume
6,259
Previous Close
$0.55
Day Range
$0.55 – $0.58
EPS
-$38.57
Revenue
$0.00
Net Income
-$15.75M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
6
MBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$15.75M | -$51.60M | -$77.53M | -$66.37M |
| EPS (Diluted) | -$38.57 | -$299.95 | -$10.09 | -$0.76 |
Total Assets
$9.31M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$6.84M
Operating Cash Flow
-$11.41M
Free Cash Flow
$0.00
Mustang Bio Inc Company Information
- President, CEO, Interim CFO & Director
- Manuel Litchman M.D.
- Headquarters
- 95 Sawyer Road, Waltham, MA, United States, 02453
- Website
- www.mustangbio.com
- Phone
- 781 652 4500
- IPO / Founded
- 2017-08-22
- Sector
- Healthcare
- Industry
- Biotechnology